Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.

• DOI: 10.1200/jco.2017.35.15_suppl.e20626
• Publication Date: 2018-09-06T15:54:26Z
• Authors: Si-Yu Wang; Zui Liu; Wei Ou; Ning Li; Hui-qi Wu; Xiao-Yong Mao; Cheng Yuan
• Keywords: Apatinib; Clinical endpoint; Targeted Therapy; Progression-free survival

e20626 Background: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), has been proved to be effective and safe in treating patients with advanced gastric cancer who failed second-line chemotherapy. As the VEGFR-2 targeted therapy made encouraging progress treatment broad range malignancies, we aimed explore efficacy safety apatinib non-small cell lung after failure chemotherapy or other therapy. Methods: In this open-label single-arm, phase II study, were treated alone daily dose 250 mg, po, second- third-line setting. The primary endpoint was progression-free-survival (PFS) tumor response determined according Response Evaluation Criteria Solid Tumors (RECIST) Version 1.1. Results: From January 28, 2016 December 31, 2016, 33 enrolled, including 9 squamous carcinoma 24 adenocarcinoma. Fourteen detected as EGFR mutations all cases have no anaplastic lymphoma kinase (ALK) fusion gene. median progression free survival (mPFS) whole group 4.0 (95% confidence interval [CI], 0-8.2) months, while mPFS adenocarcinoma CI, 2.1-5.9) months 5.5 0-13.9) (P = 0.245). Among patients, partial noted 3 (9.09 %) stable disease 14 (42.42%). control rate (DCR) 51.52%. common side effects hypertension, hand-foot syndrome proteinuria, which accounted for 33.33%, 24.24%, 15.15%, grade 3/4 adverse reactions occurred. toxicity controllable tolerable. Conclusions: Apatinib appears Prospective studies are needed further investigation.